These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 35998294)
1. Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis. Leung JH; Tai YS; Wang SY; Tsung-Chin H; Yip Fion HT; Chan AL; Yu-Chen H Expert Opin Drug Saf; 2023 Mar; 22(3):243-252. PubMed ID: 35998294 [TBL] [Abstract][Full Text] [Related]
2. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Schettini F; Venturini S; Giuliano M; Lambertini M; Pinato DJ; Onesti CE; De Placido P; Harbeck N; Lüftner D; Denys H; Van Dam P; Arpino G; Zaman K; Mustacchi G; Gligorov J; Awada A; Campone M; Wildiers H; Gennari A; Tjan-Heijnen V; Bartsch R; Cortes J; Paris I; Martín M; De Placido S; Del Mastro L; Jerusalem G; Curigliano G; Prat A; Generali D Cancer Treat Rev; 2022 Dec; 111():102468. PubMed ID: 36202026 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM Future Oncol; 2024; 20(22):1587-1600. PubMed ID: 38597713 [No Abstract] [Full Text] [Related]
4. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598 [TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Nagayama A; Vidula N; Bardia A Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696 [TBL] [Abstract][Full Text] [Related]
6. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
7. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Li CH; Karantza V; Aktan G; Lala M Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Shi M; Li Z; Shen G; Wang T; Li J; Wang M; Liu Z; Zhao F; Ren D; Zhao J Cancer Pathog Ther; 2024 Apr; 2(2):81-90. PubMed ID: 38601487 [TBL] [Abstract][Full Text] [Related]
9. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316 [TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
11. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695 [TBL] [Abstract][Full Text] [Related]
12. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Chen H; Lu W; Zhang Y; Zhu X; Zhou J; Chen Y Cancer Med; 2019 Jan; 8(1):383-399. PubMed ID: 30525293 [TBL] [Abstract][Full Text] [Related]
13. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P; Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935 [TBL] [Abstract][Full Text] [Related]
15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363 [TBL] [Abstract][Full Text] [Related]
16. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N Trials; 2015 Dec; 16():575. PubMed ID: 26673577 [TBL] [Abstract][Full Text] [Related]
17. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA; N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906 [TBL] [Abstract][Full Text] [Related]
18. Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials. Tian Q; Du P; Li S; Bai Z; Yang Y; Zeng J Medicine (Baltimore); 2017 Nov; 96(45):e8389. PubMed ID: 29137021 [TBL] [Abstract][Full Text] [Related]
19. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer. Kang C; Syed YY Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356 [TBL] [Abstract][Full Text] [Related]
20. Metastatic triple-negative breast cancer: Established and emerging treatments. Puri A; Reddy TP; Patel TA; Chang JC Breast J; 2020 Sep; 26(9):1793-1796. PubMed ID: 32578306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]